Kaiser Health Network
This article was produced by Kaiser Health News with support from The SCAN Foundation.
http://www.kaiserhealthnews.org/stories/2012/march/13/off-label-use-of-risky-antipsychotic-drugs.aspx (Source: PharmaGossip)
Source: PharmaGossip - February 15, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Lilly Threatens To Leave Canada Over Patent Rulings
After a series of losses in Canadian courts over patents for several key drugs, Eli Lilly ceo John Lechleiter is now threatening to move operations out of the country. Why? The defeats over the patents for the Strattera ADHD drug, the Zyprexa antipsychotic and the Evista osteoporosis treatment have cost Lilly more than $1 billion in revenue and prompted some 280 jobs cuts since 2006, leaving the drugmaker with about 500 employees in Canada.
“If that sort of pattern persists, it’s not a question of would we stay in Canada, it’s a question of would we have any business in Canada,” Lechleiter told a meeting of the edi...
Source: Pharmalot - February 14, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Boehringer Ingelheim Eli Lilly Evista JJ jobs John Lechleiter Johnson & Johnson Merck NAFTA Pfizer Sanofi Strattera Zyprexa Source Type: blogs
Medications that Increase the Risks of Patient Falls
Falls are the leading cause of both fatal and non-fatal injuries for adults 65 and older.
Alzheimer's Reading Room
“Falls are the leading cause of both fatal and non-fatal injuries for adults 65 and older, and research suggests that those taking four or more medications are at an even greater risk than those who don’t – perhaps two to three times greater,” said Susan Blalock, Ph.D., an associate professor at the UNC Eshelman School of Pharmacy.
In 2007, more than 21,700 Americans died as a result of falls and more than 7.9 million were injured by a fall including over 1.8 million older adults who had a fall-rela...
Source: Alzheimer's Reading Room, The - February 14, 2013 Category: Dementia Authors: Bob DeMarco Source Type: blogs
Lilly hit by Zyprexa losses | Pharmafile
Published on 30/01/13 at 11:33am The loss of exclusivity on Eli Lilly’s blockbuster antipsychotic Zyprexa hit the company hard in 2012, with the firm’s overall revenue falling 7% worldwide. The drug itself, licensed to treat schizophrenia and bipolar disorder, brought in as much as $5 billion in 2010, but had sales of just $1.7 billion last year - down 63% on 2011’s figure. Lilly’s turnover fell to $22.6 billion, although its pre-tax profit of $5.4 billion was up 1% year-on-year. Life without Zyprexa is proving as tough as Lilly predicted a year ago, and its troubles are far from over. Sales of an...
Source: PharmaGossip - January 30, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Selling Zyprexa - a "must read"!
https://doxosophia.files.wordpress.com/2011/03/the-globalization-of-pharmaceutical-damage-control.pdf (Source: PharmaGossip)
Source: PharmaGossip - January 30, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Physician Payment Sunshine Act: Many Letters to Encourage Completion of Regulations, Disclosures Use in Malpractice Cases
As we continue to wait for the final regulations to implement the Physician Payment Sunshine Act, more groups are writing to the White House’s Office of Management and Budget (OMB) urging the Obama Administration to release the rule. Last week, AARP, AFL-CIO, and 17 other healthcare advocacy groups issued a letter urging the Obama administration to roll out those regulations ASAP. “After all, the legislation is aimed at holding the line on healthcare costs--by minimizing pharma influence on brand-name prescribing--and at protecting patients from unhealthy results of untoward financial relationships, the groups wrot...
Source: Policy and Medicine - January 22, 2013 Category: Health Medicine and Bioethics Commentators Authors: Thomas Sullivan Source Type: blogs
Pharma Deals North of $10 Billion Seen Returning in 2013 - Bloomberg
Get ready for the return of the $10 billion-plus drug deal. Pharmaceutical companies including Pfizer Inc. (PFE) and Bristol- Myers Squibb Co. (BMY) have spent the last several years digesting earlier acquisitions, refocusing their product development and setting aside cash in anticipation of expiring patents. Now, the expectation is they’re ready to start buying again. Led by Pfizer, in New York, and Whitehouse Station, New Jersey-based Merck & Co. (MRK), five of the largest U.S. drugmakers had more than $70 billion in cash, near cash and short-term investments at the end of the third quarter. ...
Source: PharmaGossip - January 7, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Overmedicating Patients & Speaking For Drugmakers
A jury in upstate New York recently found that a doctor’s negligence caused a patient to commit suicide by overmedicating him with psychiatric drugs. As it turns out, the same doctor was also paid more than $200,000 by various drugmakers for more than a decade to promote some of the same psychiatric medicines to other doctors, The Syracuse Post-Standard reports.
There is more. William Beals, 61, a family medicine doctor in Liverpool, New York, was disciplined by the state early last year for prescribing drugs to patients for years without ever seeing them in his office, the paper writes. In September, he was censured...
Source: Pharmalot - January 2, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Cymbalta Effexor Eli Lilly GlaxoSmithKline Paxil Pfizer Zyprexa Source Type: blogs
